GSK (LSE: GSK) posted a 6% rise in second-quarter sales to £8 billion ($10.7 billion), ahead of analyst forecasts. Pre-tax ...

As July concludes, the landscape of hematologic oncology continues to evolve, with notable progress in multiple myeloma, ...

With a portfolio of 14 potential blockbuster treatments that it expects to launch over the next five years, GSK is sticking ...

GSK tops Q2 estimates with growth in vaccines and specialty drugs, raises 2025 forecast amid progress in major late-stage ...

GSK expects to deliver annual sales and profit growth towards the top end of its forecasts after beating second-quarter ...

GSK Plc reported better-than-expected profit and raised its estimates for revenue at two key divisions in a report that ...

SALES FORECAST: The U.K. pharmaceutical company is expected to report sales of 7.8 billion pounds ($10.42 billion), according to consensus estimates compiled by the company. For last year's second ...

Shares of GSK fell to below $30 around the time of the demerger, but have since recovered to about $36. The 20% gain over 34 ...

European regulators on Friday said that the Duchenne muscular dystrophy gene therapy Elevidys should not be approved ...

The combinations are also approved for relapsed or refractory multiple myeloma in Japan, the UK and other markets including ...

(Alliance News) - GSK PLC on Thursday said its Blenrep blood cancer treatment has been approved in Europe, as it awaits a final decision from the US regulator. The London-based pharmaceutical firm ...

The EU approves belantamab mafodotin combinations, enhancing treatment options for relapsed multiple myeloma patients with ...